{"entity": "researcher", "timestamp": "2026-08-20T20:49:49.176Z", "family": "Ellingsen", "given": "Espen Basmo", "initials": "EB", "orcid": "0000-0002-0235-1184", "affiliations": ["Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway espen.ellingsen@ultimovacs.com.", "Faculty of Medicine, University of Oslo, Oslo, Norway.", "Ultimovacs ASA, Oslo, Norway."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/41e26c29bfdc4fba86d34336f0832e67.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/41e26c29bfdc4fba86d34336f0832e67"}}, "publications": [{"entity": "publication", "iuid": "4973156507cd46949fb207c50ae1b9f1", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/4973156507cd46949fb207c50ae1b9f1.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/4973156507cd46949fb207c50ae1b9f1"}}, "title": "Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.", "authors": [{"family": "Ellingsen", "given": "Espen Basmo", "initials": "EB", "orcid": "0000-0002-0235-1184", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/41e26c29bfdc4fba86d34336f0832e67.json"}}, {"family": "Bounova", "given": "Gergana", "initials": "G"}, {"family": "Kerzeli", "given": "Iliana", "initials": "I"}, {"family": "Anzar", "given": "Irantzu", "initials": "I"}, {"family": "Simnica", "given": "Donjete", "initials": "D"}, {"family": "Aamdal", "given": "Elin", "initials": "E"}, {"family": "Guren", "given": "Tormod", "initials": "T"}, {"family": "Clancy", "given": "Trevor", "initials": "T"}, {"family": "Mezheyeuski", "given": "Artur", "initials": "A"}, {"family": "Inderberg", "given": "Else Marit", "initials": "EM"}, {"family": "Mangsbo", "given": "Sara M", "initials": "SM"}, {"family": "Binder", "given": "Mascha", "initials": "M"}, {"family": "Hovig", "given": "Eivind", "initials": "E"}, {"family": "Gaudernack", "given": "Gustav", "initials": "G"}], "type": "clinical trial, phase i", "published": "2022-09-11", "journal": {"title": "J Transl Med", "issn": "1479-5876", "volume": "20", "issue": "1", "pages": "419", "issn-l": "1479-5876"}, "abstract": "This clinical trial evaluated a novel telomerase-targeting therapeutic cancer vaccine, UV1, in combination with ipilimumab, in patients with metastatic melanoma. Translational research was conducted on patient-derived blood and tissue samples with the goal of elucidating the effects of treatment on the T cell receptor repertoire and tumor microenvironment.\n\nThe trial was an open-label, single-center phase I/IIa study. Eligible patients had unresectable metastatic melanoma. Patients received up to 9 UV1 vaccinations and four ipilimumab infusions. Clinical responses were assessed according to RECIST 1.1. Patients were followed up for progression-free survival (PFS) and overall survival (OS). Whole-exome and RNA sequencing, and multiplex immunofluorescence were performed on the biopsies. T cell receptor (TCR) sequencing was performed on the peripheral blood and tumor tissues.\n\nTwelve patients were enrolled in the study. Vaccine-specific immune responses were detected in 91% of evaluable patients. Clinical responses were observed in four patients. The mPFS was 6.7 months, and the mOS was 66.3 months. There was no association between baseline tumor mutational burden, neoantigen load, IFN-\u03b3 gene signature, tumor-infiltrating lymphocytes, and response to therapy. Tumor telomerase expression was confirmed in all available biopsies. Vaccine-enriched TCR clones were detected in blood and biopsy, and an increase in the tumor IFN-\u03b3 gene signature was detected in clinically responding patients.\n\nClinical responses were observed irrespective of established predictive biomarkers for checkpoint inhibitor efficacy, indicating an added benefit of the vaccine-induced T cells. The clinical and immunological read-out warrants further investigation of UV1 in combination with checkpoint inhibitors. Trial registration Clinicaltrials.gov identifier: NCT02275416. Registered October 27, 2014. https://clinicaltrials.gov/ct2/show/NCT02275416?term=uv1&draw=2&rank=6.", "doi": "10.1186/s12967-022-03624-z", "pmid": "36089578", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC9465869"}, {"db": "pii", "key": "10.1186/s12967-022-03624-z"}, {"db": "ClinicalTrials.gov", "key": "NCT02275416"}], "notes": [], "created": "2026-08-20T12:20:50.725Z", "modified": "2026-08-20T12:20:50.787Z"}, {"entity": "publication", "iuid": "6c2b490e448a4b259164b54862d5b470", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/6c2b490e448a4b259164b54862d5b470.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/6c2b490e448a4b259164b54862d5b470"}}, "title": "Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials.", "authors": [{"family": "Ellingsen", "given": "Espen Basmo", "initials": "EB", "orcid": "0000-0002-0235-1184", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/41e26c29bfdc4fba86d34336f0832e67.json"}}, {"family": "Aamdal", "given": "Elin", "initials": "E"}, {"family": "Guren", "given": "Tormod", "initials": "T"}, {"family": "Lilleby", "given": "Wolfgang", "initials": "W"}, {"family": "Brunsvig", "given": "Paal F", "initials": "PF"}, {"family": "Mangsbo", "given": "Sara M", "initials": "SM"}, {"family": "Aamdal", "given": "Steinar", "initials": "S"}, {"family": "Hovig", "given": "Eivind", "initials": "E"}, {"family": "Mensali", "given": "Nadia", "initials": "N"}, {"family": "Gaudernack", "given": "Gustav", "initials": "G"}, {"family": "Inderberg", "given": "Else Marit", "initials": "EM"}], "type": "journal article", "published": "2022-05-00", "journal": {"title": "J Immunother Cancer", "issn": "2051-1426", "volume": "10", "issue": "5", "issn-l": null}, "abstract": "Therapeutic cancer vaccines represent a promising approach to improve clinical outcomes with immune checkpoint inhibition. UV1 is a second generation telomerase-targeting therapeutic cancer vaccine being investigated across multiple indications. Although telomerase is a near-universal tumor target, different treatment combinations applied across indications may affect the induced immune response. Three phase I/IIa clinical trials covering malignant melanoma, non-small cell lung cancer, and prostate cancer have been completed, with patients in follow-up for up to 8 years.\n\n52 patients were enrolled across the three trials. UV1 was given as monotherapy in the lung cancer trial and concurrent with combined androgen blockade in the prostate cancer trial. In the melanoma study, patients initiated ipilimumab treatment 1 week after the first vaccine dose. Patients were followed for UV1-specific immune responses at frequent intervals during vaccination, and every 6 months for up to 8 years in a follow-up period. Phenotypic and functional characterizations were performed on patient-derived vaccine-specific T cell responses.\n\nIn total, 78.4% of treated patients mounted a measurable vaccine-induced T cell response in blood. The immune responses in the malignant melanoma trial, where UV1 was combined with ipilimumab, occurred more rapidly and frequently than in the lung and prostate cancer trials. In several patients, immune responses peaked years after their last vaccination. An in-depth characterization of the immune responses revealed polyfunctional CD4+ T cells producing interferon-\u03b3 and tumor necrosis factor-\u03b1 on interaction with their antigen.\n\nLong-term immunomonitoring of patients showed highly dynamic and persistent telomerase peptide-specific immune responses lasting up to 7.5 years after the initial vaccination, suggesting a plausible functional role of these T cells in long-term survivors. The superior immune response kinetics observed in the melanoma study substantiate the rationale for future combinatorial treatment strategies with UV1 vaccination and checkpoint inhibition for rapid and frequent induction of anti-telomerase immune responses in patients with cancer.", "doi": "10.1136/jitc-2021-004345", "pmid": "35613827", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC9134181"}, {"db": "pii", "key": "jitc-2021-004345"}], "notes": [], "created": "2026-08-20T12:02:15.097Z", "modified": "2026-08-20T12:02:15.151Z"}]}